What is it about?
SUmmary of genetics, prognostic impact and targeting of polo-like kinases in non-small cell lung cancer.
Featured Image
Photo by Franck V. on Unsplash
Why is it important?
Target therapy is a fundamental treatment strategy in NSCLC. PLK1 has been recognized as an important driver of tumorigenesis and mechanism of resistance in the treatent of NSCLC. We summerize the available evidence of PLK1 targeting in NSCLC so far.
Read the Original
This page is a summary of: Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers, Lung Cancer Targets and Therapy, July 2019, Dove Medical Press,
DOI: 10.2147/lctt.s177618.
You can read the full text:
Contributors
The following have contributed to this page
